ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression

Pharmacogenomics. 2013 Sep;14(12):1433-48. doi: 10.2217/pgs.13.139.

Abstract

Aim: Because 5-fluorodeoxyuridine monophosphate (5-FdUMP), an anabolic active metabolite of 5-fluorouracil (5-FU), is a substrate of MRP8 (encoded by ABCC11), we investigated whether ABCC11 polymorphisms play a role in severe toxicity of 5-FU.

Patients & methods: Genomic DNA from 672 cancer patients treated with 5-FU monotherapy and with documented toxicity according to WHO criteria was genotyped for 12 ABCC11 tag SNPs. Functional impact of polymorphisms was assessed in a Caucasian human liver cohort (n = 150) and by recombinant expression of MRP8 protein variants.

Results: Univariate and multivariate analysis identified rs17822471 (G>A, T546M) as risk factor of severe leukopenia (p = 0.021, odds ratio [95%CI]: 3.31 [1.26-8.66]) but not of other toxicity types. MRP8 protein expression in human liver was 1.7-fold lower in carriers compared with wild-type (p = 0.02). Recombinant expression confirmed the effect of T546M on protein expression.

Conclusion: Since MRP8 is expressed in bone marrow blasts and leukocytes, lower expression may lead to intracellular accumulation of 5-FdUMP and increased risk of leukopenia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP-Binding Cassette Transporters / genetics*
  • Aged
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / toxicity*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Leukopenia / chemically induced
  • Leukopenia / genetics*
  • Leukopenia / pathology
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Middle Aged
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / pathology
  • Polymorphism, Genetic
  • Polymorphism, Single Nucleotide
  • Risk Factors

Substances

  • ABCC11 protein, human
  • ATP-Binding Cassette Transporters
  • Fluorouracil